Health, beauty, and wellness is a rapidly growing industry worldwide. Stay up to date with global news, trends, topics, and more with the AIHBA news feed.
Cold Spring Harbor Laboratory (CSHL) Associate Professor Pavel Osten and Professor Lloyd Trotman have developed a new way to study the life history of prostate cancer in mice. The pair combined their expertise in whole-organ imaging and prostate cancer to track how prostate cancer cells grow into tumors and spread to other organs. Their method […]
The prostate cancer cell that got away Read More »
Prostate cancer is a leading cause of death among American men, and it’s resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers reporting in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to
A step toward treating chemotherapy-resistant prostate cancer Read More »
Prostate cancer screening results differ in men taking cholesterol-lowering statin drugs compared with non-users, a study conducted at Tampere University in Finland finds. In statin users, screening did not increase the incidence of prostate cancer as it did in other men. The study found the clearest difference in low-risk cancer, which is often overdiagnosed due
Statin use affects prostate cancer screening results Read More »
A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time. The innovation, developed by researchers at the University of Waterloo, creates images in which cancerous tissue appears to light up compared to healthy tissue, making
MRI innovation makes cancerous tissue light up and easier to see Read More »
A molecular feature in prostate cancer, called endogenous retroviral (ERV) RNA, has been found to have prognostic value and also distinguish differences between men of African and European or Middle Eastern ancestry, according to a study led by researchers at the University of California, Irvine. The team also identified ERV expression signatures that may be
Assessing Progression Risk in Cancer Read More »
Researchers at Karolinska Institutet in Sweden have together with international collaborators completed a comprehensive international validation of artificial intelligence (AI) for diagnosing and grading prostate cancer. The study, published in Nature Medicine, shows that AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as pathologists. The results suggest
AI accurately diagnoses prostate cancer, study shows Read More »
Faulty versions of the BRCA1 and BRCA2 genes are well known to increase the risk of breast cancer in men and women, and in ovarian cancer. Now BRCA1 and BRCA2 have been linked to several other cancers, including those that affect men. A study published today in the Journal of Clinical Oncology has provided the
Faulty BRCA genes linked to prostate and pancreatic cancers Read More »
A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A. Anna Ioannidou of Imperial College London, U.K., and colleagues present these findings in the open-access journal PLOS Medicine. Some factors associated with higher risk of prostate cancer cannot
Genetic clues link lipoprotein A to prostate cancer risk Read More »
The combination of a novel blood test and magnetic resonance imaging (MRI) can reduce overdiagnosis of low-risk cancers as well as societal costs in prostate cancer screening, according to a cost-effectiveness study from Karolinska Institutet published in the journal European Urology. The results provide support for organised prostate cancer testing in Sweden, researchers say. A
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team led by investigators at Massachusetts General
Thank you for visiting the AIHBA website, which language would you like to view the site in?
欢迎访问AIHBA网站!
请在下方选择您希望使用的语言，以便更好地浏览我们的网站
中文
English language